HealthInvest Partners AB Invests $4.62 Million in Amgen Inc. (NASDAQ:AMGN)

HealthInvest Partners AB purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 16,023 shares of the medical research company’s stock, valued at approximately $4,615,000. Amgen accounts for about 3.6% of HealthInvest Partners AB’s portfolio, making the stock its 9th biggest holding.

A number of other hedge funds have also bought and sold shares of AMGN. OFI Invest Asset Management bought a new position in Amgen during the third quarter worth about $26,000. Briaud Financial Planning Inc bought a new position in Amgen during the third quarter worth about $26,000. Strategic Investment Solutions Inc. IL bought a new position in Amgen during the first quarter worth about $28,000. BOK Financial Private Wealth Inc. bought a new position in Amgen during the fourth quarter worth about $29,000. Finally, Providence Capital Advisors LLC bought a new position in Amgen in the 3rd quarter valued at about $30,000. 76.50% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on AMGN shares. The Goldman Sachs Group raised their target price on shares of Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. Morgan Stanley decreased their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $329.00 target price on shares of Amgen in a report on Wednesday, April 3rd. Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. Finally, BMO Capital Markets raised shares of Amgen from a “market perform” rating to an “outperform” rating and raised their target price for the company from $286.00 to $326.00 in a report on Tuesday, December 19th. Ten research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Amgen has an average rating of “Hold” and an average price target of $295.30.

Amgen Trading Up 0.0 %

NASDAQ:AMGN traded up $0.13 during mid-day trading on Tuesday, hitting $265.64. 2,017,570 shares of the company’s stock were exchanged, compared to its average volume of 2,871,780. The company has a 50 day simple moving average of $279.63 and a 200-day simple moving average of $281.52. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72. The firm has a market capitalization of $142.36 billion, a P/E ratio of 21.26, a PEG ratio of 2.53 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping the consensus estimate of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. During the same period last year, the company earned $4.09 EPS. The firm’s revenue was up 19.8% compared to the same quarter last year. As a group, research analysts expect that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.39%. Amgen’s dividend payout ratio (DPR) is currently 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.